Truist Financial Corp Sells 8,062 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Truist Financial Corp trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 44,381 shares of the biopharmaceutical company's stock after selling 8,062 shares during the period. Truist Financial Corp's holdings in Regeneron Pharmaceuticals were worth $38,979,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CX Institutional raised its holdings in shares of Regeneron Pharmaceuticals by 10.7% in the 3rd quarter. CX Institutional now owns 311 shares of the biopharmaceutical company's stock worth $256,000 after purchasing an additional 30 shares in the last quarter. Valeo Financial Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 20.0% in the third quarter. Valeo Financial Advisors LLC now owns 619 shares of the biopharmaceutical company's stock valued at $509,000 after buying an additional 103 shares in the last quarter. HCR Wealth Advisors acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $202,000. Atlantic Union Bankshares Corp boosted its stake in shares of Regeneron Pharmaceuticals by 17.3% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 1,106 shares of the biopharmaceutical company's stock worth $910,000 after acquiring an additional 163 shares in the last quarter. Finally, PDS Planning Inc grew its holdings in shares of Regeneron Pharmaceuticals by 8.3% in the 3rd quarter. PDS Planning Inc now owns 338 shares of the biopharmaceutical company's stock worth $278,000 after acquiring an additional 26 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Andrew J. Murphy sold 5,783 shares of the company's stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the company's stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares of the company's stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 11,022 shares of company stock valued at $10,552,991 over the last quarter. Insiders own 8.83% of the company's stock.

Regeneron Pharmaceuticals Stock Up 1.1 %

REGN traded up $9.28 during midday trading on Monday, hitting $892.48. 365,689 shares of the company's stock traded hands, compared to its average volume of 489,599. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The company has a market cap of $97.96 billion, a PE ratio of 25.68, a price-to-earnings-growth ratio of 2.54 and a beta of 0.11. The stock's fifty day simple moving average is $946.89 and its 200-day simple moving average is $894.83. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts' consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals's revenue for the quarter was up .6% on a year-over-year basis. During the same quarter last year, the firm earned $10.96 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an "outperform" rating and a $1,125.00 target price for the company. Barclays raised their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an "overweight" rating in a report on Tuesday, January 23rd. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 20th. Royal Bank of Canada restated an "outperform" rating and issued a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Finally, TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a "buy" rating in a research report on Wednesday, April 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $977.77.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.